



EAPCI
European Association of
Percutaneous Cardiovascular
Interventions



ESC
European Society
of Cardiology

European Association of Percutaneous Cardiovascular Interventions

Salvatore Brugaletta
Country : Spain

**Application for the following position in the EAPCI Board 2024-2026:
PCR representative**

Current position

Interventional Cardiologist at Hospital Clinic, Barcelona, Spain

Profession

- Interventionalist
- Healthcare Professional (Nurse, Radiographer, Technician) working in PCI
- Other (specify)

Additional Information

- Fellow of the ESC
- EAPCI Member
- Member of another ESC Association (beyond EAPCI)
If yes, specify:
- Active in an ESC Member Country
If yes, specify your country of work: Spain
- Member of a National Cardiac Society
If yes, specify: Spanish Society of interventional Cardiology
- Member of an Interventional Working Group
If yes, specify: Working group on coronary pathophysiology & microcirculation

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

General CV (as it pertains to PCI) – 300 words max

I am an interventional cardiologist with large experience in ischemic heart and valvular disease treatment, with use of coronary physiology, intracoronary imaging (IVUS, OCT, NIRS) and CHIP cases, performing more than 400 PCI/year and 70 TAVI/year.

I had my medical and cardiology degrees from the Catholic University of the Sacred Heart in Rome, under the direction of prof. Filippo Crea. I attended a 2-year clinical fellowship in interventional cardiology at the Hospital of “Santa Creu I Sant Pau”, Barcelona, Spain, under the supervision of prof. Manel Sabate. I did also a 2-year research fellowship at the Thoraxcenter in Rotterdam, the Netherlands, under the direction of prof. Patrick W. Serruys. I got 2 PhD, one in molecular and cellular cardiology at the Catholic University of the Sacred Heart, Rome, and one in interventional cardiology at the “Erasmus universiteit”, Rotterdam.

My research interest started in the field of atherosclerosis and in particular of the inflammation related to coronary plaque in acute coronary syndromes. I have studied role of CTO-PCI in recovering coronary vascular function and possible recovery action of ticagrelor (TICA-GR-ELOR and ABSORB Bioresorbable Vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization, TIGER-BVS, NCT02211066). I was also involved in many studies investigating bioresorbable vascular scaffolds and I acted as primary investigator or in the steering committee in trials focusing on the role of bioresorbable scaffold in STEMI patients (TROFI-II, MAGSTEMI trial). I also investigated long-term prognosis of STEMI patients included in the EXAMINATION trial, promoting the extension of their follow-up up to 10 years.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Previous experience in EAPCI, ESC or your National Bodies

Specifically, please indicate if you hold an Executive position (President, Vice President, President Elect) in a National Cardiac Society or in the ESC. If so, please indicate which one as well as the term of this position.

If you have been involved in EAPCI in the past, please specify the position(s) as well as the relevant date(s)

In particular, please indicate if you served in:

- | | | |
|---|------------|-----------|
| • EAPCI Board 2022-2024 (under E. Barbato's leadership)? | Yes | No |
| • EAPCI Board 2020-2022 (under D. Dudek's leadership)? | Yes | No |
| • EAPCI Board 2018-2020 (under A. Baumbach's leadership)? | Yes | No |
| • EAPCI Board 2016-2018 (under M. Haude's leadership)? | Yes | No |

If you answered yes to at least one of these questions, please provide details.

- Member of the EAPCI young committee (2016-2018)
- Chairman of the EAPCI "New Initiative for Young Interventionalists committee" 2018-2020
- Member of the EAPCI "Database & Registries committee" 2018-2020
- Member of the EAPCI "Databases and registries committee" 2020-2022
- Member of the EAPCI "Innovations and digital cardiology committee" 2020-2022
- Member of EAPCI "Scientific documents committee" 2022-2024

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Publications in the field of PCI (most important 10 publications)

1. [10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.](#)
Brugaletta S, Gomez-Lara J, Ortega-Paz L, Jimenez-Diaz V, Jimenez M, Jiménez-Quevedo P, Diletti R, Mainar V, Campo G, Silvestro A, Maristany J, Flores X, Oyarzabal L, De Miguel-Castro A, Iñiguez A, Serra A, Nombela-Franco L, Ielasi A, Tespili M, Lenzen M, Gonzalo N, Bordes P, Tebaldi M, Biscaglia S, Rodriguez-Arias JJ, Al-Shaibani S, Arevalos V, Romaguera R, Gomez-Hospital JA, Serruys PW, Sabaté M. **J Am Coll Cardiol.** 2021 Mar 9;77(9):1165-1178. doi: 10.1016/j.jacc.2020.12.059.
2. [Sex Differences in 10-Year Outcomes Following STEMI: A Subanalysis From the EXAMINATION-EXTEND Trial.](#)
Gabani R, Spione F, Arevalos V, Grima Sopesens N, Ortega-Paz L, Gomez-Lara J, Jimenez-Diaz V, Jimenez M, Jiménez-Quevedo P, Diletti R, Pineda J, Campo G, Silvestro A, Maristany J, Flores X, Oyarzabal L, Bastos-Fernandez G, Iñiguez A, Serra A, Escaned J, Ielasi A, Tespili M, Lenzen M, Gonzalo N, Bordes P, Tebaldi M, Biscaglia S, Al-Shaibani S, Romaguera R, Gomez-Hospital JA, Rodes-Cabau J, Serruys PW, Sabaté M, Brugaletta S. **JACC Cardiovasc Interv.** 2022 Oct 10;15(19):1965-1973. doi: 10.1016/j.jcin.2022.07.038. Epub 2022 Aug 22.
3. [Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation.](#)
Coughlan JJ, Räber L, **Brugaletta S**, Kufner S, Maeng M, Jensen LO, Ortega-Paz L, Bär S, Laugwitz KL, Madsen M, Heg D, Aytekin A, Windecker S, Olesen KKW, Sabaté M, Kastrati A, Cassese S. **Circulation.** 2023 Feb 14;147(7):575-585. doi: 10.1161/CIRCULATIONAHA.122.062049. Epub 2023 Feb 13.
4. [Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial.](#)
Sabaté M, Alfonso F, Cequier A, Romaní S, Bordes P, Serra A, Iñiguez A, Salinas P, García Del Blanco B, Goicolea J, Hernández-Antolín R, Cuesta J, Gómez-Hospital JA, Ortega-Paz L, Gomez-Lara J, **Brugaletta S**. **Circulation.** 2019 Dec 3;140(23):1904-1916. doi: 10.1161/CIRCULATIONAHA.119.043467. Epub 2019 Sep 25.
5. [Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome \(MATRIX\): final 1-year results of a multicentre, randomised controlled trial.](#)
Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, **Brugaletta S**, Windecker S, Heg D, Jüni P; MATRIX Investigators. **Lancet.** 2018 Sep 8;392(10150):835-848. doi: 10.1016/S0140-6736(18)31714-8. Epub 2018 Aug 25.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

6. [Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.](#)
Yamaji K, **Brugaletta S**, Sabaté M, Iñiguez A, Jensen LO, Cequier A, Hofma SH, Christiansen EH, Suttorp M, van Es GA, Sotomi Y, Onuma Y, Serruys PW, Windecker S, Räber L. *JACC Cardiovasc Interv.* 2017 Sep 25;10(18):1867-1877. doi: 10.1016/j.jcin.2017.07.035.
7. [Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents \(EXAMINATION\): 5-year results of a randomised trial.](#)
Sabaté M, **Brugaletta S**, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Trespili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, Valgimigli M, Serruys PW. *Lancet.* 2016 Jan 23;387(10016):357-366. doi: 10.1016/S0140-6736(15)00548-6. Epub 2015 Oct 29.
8. [Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.](#)
Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A, **Brugaletta S**, Hofma SH, Räber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G, Sotomi Y, García-García HM, Onuma Y, Serruys PW. *Eur Heart J.* 2016 Jan 14;37(3):229-40. doi: 10.1093/eurheartj/ehv500. Epub 2015 Sep 23.
9. [Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study \(bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction\).](#)
Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, Sabaté M. *JACC Cardiovasc Interv.* 2015 Jan;8(1 Pt B):189-197. doi: 10.1016/j.jcin.2014.10.005.
10. [Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?](#)
Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. *Eur Heart J.* 2012 Jun;33(11):1325-33. doi: 10.1093/eurheartj/ehr466. Epub 2012 Apr 16.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

What would you like to achieve if you were elected? Please provide your 3 main topics (max 500 words)

1. Fruitful collaboration between EAPCI, PCR and national working groups

I would like to promote a full and deep collaboration between EAPCI, PCR and national working groups in order to achieve common objectives in terms of certification, learning, registries, etc.

2. Learning resources for fellows and interventional cardiologists at early stage

Based on the collaboration between EAPCI, PCR and national working groups, I would like to promote and to make easy to access learning resources for fellows and interventional cardiologists, not only in terms of courses, congresses, etc, but also in terms of possibility of training in different countries in specific techniques, such as imaging, physiology, CHIP, TAVI, etc.

3. To improve EAPCI certification, being it recognized at each national level.

I would like to promote the academical recognition of EAPCI certification at the national level.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

If you were elected, how do you envisage to organize yourself to accommodate this very time demanding additional commitment?

I do not think it would be a problem to deal with such additional commitment.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.